To test if the TRAIL sensitization of pancreatic cancer cells by GSK-3 inhibition is caspase-dependent, PANC-1 and BxPC-3 cells were treated with 25 μM AR-18 and/or 10 ng/mL TRAIL in the presence of the general caspase inhibitor z-VAD-fmk. This evidence concerns the gene TNFSF10 and familial pancreatic carcinoma.